- Report
- October 2024
- 183 Pages
Global
From €3383EUR$3,545USD£2,835GBP
€3759EUR$3,939USD£3,150GBP
- Report
- March 2025
- 356 Pages
Global
From €5201EUR$5,450USD£4,358GBP
- Report
- August 2024
- 141 Pages
Global
From €2862EUR$2,999USD£2,398GBP
- Report
- March 2025
- 200 Pages
Global
From €4285EUR$4,490USD£3,590GBP
- Report
- June 2024
- 200 Pages
Global
From €7587EUR$7,950USD£6,357GBP
- Clinical Trials
- June 2024
- 240 Pages
Global
From €2863EUR$3,000USD£2,399GBP
- Report
- June 2024
- 200 Pages
Global
From €7587EUR$7,950USD£6,357GBP
- Clinical Trials
- April 2024
- 180 Pages
Global
From €2386EUR$2,500USD£1,999GBP
- Drug Pipelines
- April 2024
- 60 Pages
Global
From €1909EUR$2,000USD£1,599GBP
- Report
- August 2023
- 122 Pages
Global
From €4438EUR$4,650USD£3,718GBP
- Report
- August 2022
- 118 Pages
Global
From €4295EUR$4,500USD£3,598GBP
- Report
- January 2022
- 60 Pages
Global
From €3770EUR$3,950USD£3,159GBP
- Report
- January 2022
- 60 Pages
Global
From €3770EUR$3,950USD£3,159GBP
- Report
- January 2022
- 60 Pages
Global
From €3770EUR$3,950USD£3,159GBP
- Report
- April 2023
- 147 Pages
Global
From €4723EUR$4,949USD£3,957GBP
- Report
- April 2021
- 120 Pages
Global
€20996EUR$22,000USD£17,592GBP
- Report
- February 2024
- 137 Pages
Global
From €4533EUR$4,750USD£3,798GBP
- Report
- September 2023
- 79 Pages
Global
From €9539EUR$9,995USD£7,992GBP
- Report
- June 2020
- 37 Pages
Global
From €3813EUR$3,995USD£3,195GBP
- Report
- August 2022
United States
From €1851EUR$1,940USD£1,551GBP

Acute Myeloid Leukemia (AML) is a type of cancer that affects the blood and bone marrow. It is the most common type of acute leukemia in adults. Treatment for AML typically involves chemotherapy, radiation therapy, and stem cell transplantation. Drugs used to treat AML include cytarabine, daunorubicin, and idarubicin. These drugs are used to kill cancer cells, reduce the size of tumors, and reduce the risk of relapse. Other drugs used to treat AML include decitabine, gemtuzumab ozogamicin, and venetoclax. These drugs are used to target specific genetic mutations that are associated with AML.
The AML drug market is highly competitive, with many companies offering a variety of treatments. Some of the major players in the market include Novartis, Pfizer, Celgene, Bristol-Myers Squibb, and Merck. Other companies in the market include AbbVie, AstraZeneca, Johnson & Johnson, and Sanofi. Show Less Read more